Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir

AIDS

Volumn 19, Issue 17, 2005, Pages 1987-1994

  Karrer, Urs ^a   Ledergerber, Bruno ^a   Furrer, Hansjakob ^b   Elzi, Luigia ^c   Battegay, Manuel ^c   Cavassini, Matthias ^d   Gayet Ageron, Angèle ^e   Hirschel, Bernard ^e   Schmid, Patrick ^f   Russotti, Marina ^g   Weber, Rainer ^a   Speck, Roberto F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f Cantonal Hospitals of St Gallen   (Switzerland)

^g Hospital of Lugano   (Switzerland)

Author keywords

Antiretroviral therapy; CD4 cell count; Didanosine; Drug interactions; Immune recovery; Reverse transcriptase inhibitor; Tenofovir

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; HYDROXYUREA; INTERLEUKIN 2; RIBAVIRIN; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; BODY WEIGHT; CELL COUNT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE;

EID: 27944511495     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000194136.73876.9c     Document Type: Article

References (28)

1. Hawkins T. Impact of once-and twice-daily dosing regimens on adherence and overall safety. AIDS Read 2004; 14:320-322; 324, 329-331, 334-336.
2. Maggiolo F, Ripamonti D, Suter F. Once-a-day HAART: dream or reality? HIV Clin Trials 2003; 4:193-201.
3. Pecora Fulco P, Kirian MA. Effect of tenofovir on didanosine absorption in patients with HIV. Ann Pharmacother 2003; 37:1325-1328.
4. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004; 43:595-612.
5. Negredo E, Molto J, Burger D, Viciana P, Ribera E, Paredes R, et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 2004; 18:459-463.
6. Barrios A, Rendon A, Negredo E, Barreiro P, Garcia-Benayas T, Labarga P, et al. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS 2005; 19:569-575.
7. Lacombe K, Pacanowski J, Meynard JL, Trylesinski A, Girard PM. Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen. AIDS 2005; 19:1107-1108.
8. Negredo E, Puig J, Masmitja E, Molto J, Ruiz L, Clotet B. CD4 cell count changes after reduction of didanosine dosage in patients receiving standard doses of didanosine and tenofovir-based regimens. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Abstract No H561 Washington, DC, October-November 2004.
9. Ledergerber B, von Overbeck J, Egger M, Luthy R. The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Praventivmed 1994; 39:387-394.
10. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-868.
11. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
12. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003; 163:2187-2195.
13. Viard JP, Mocroft A, Chiesi A, Kirk O, Roge B, Panos G, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 2001; 183:1290-1294.
14. Grabar S, Kousignian I, Sobel A, Le Bras P, Gasnault J, Enel P, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 2004; 18:2029-2038.
15. Tung MY, Mandalia S, Bower M, Gazzard B, Nelson M. The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily. HIV Med 2005; 6:151-154.
16. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-1805.
17. Blanchard JN, Wohlfeiler M, Canas A, King K, Lonergan JT. Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected]. Clin Infect Dis 2003; 37:57-62.
18. Martinez E, Milinkovic A, de Lazzari E, Ravasi G, Blanco JL, Larrousse M, et al. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Lancet 2004; 364:65-67.
19. Grasela TH, Walawander CA, Beltangady M, Knupp CA, Martin RR, Dunkle LM, et al. Analysis of potential risk factors associated with the development of pancreatitis in phase I patients with AIDS or AIDS-related complex receiving didanosine. J Infect Dis 1994; 169:1250-1255.
20. Ray AS, Olson L, Fridland A. Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother 2004; 48:1089-1095.
21. Yarchoan R, Mitsuya H, Pluda JM, Marczyk KS, Thomas RV, Hartman NR, et al. The National Cancer Institute phase I study of 2′,3′- dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles. Rev Infect Dis 1990; 12 (suppl 5):522-533.
22. Eron JJ Jr, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, et al. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS 2000; 14:1601-1610.
23. Gathe J Jr, Badaro R, Grimwood A, Abrams L, Klesczewski K, Cross A, et al. Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir. J Acquir Immune Defic Syndr 2002; 31:399-403.
24. Kakuda TN, Anderson PL, Becker SL. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. AIDS 2004; 18:2442-2444.
25. Mitchell BS, Kelley WN. Purinogenic immunodeficiency diseases: clinical features and molecular mechanisms. Ann Intern Med 1980; 92:826-831.
26. Maitland D, Moyle G, Hand J, Mandalia S, Boffito M, Nelson M, et al. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/ efavirenz: 12-week results from a randomized trial. AIDS 2005; 19:1183-1188.
27. Podzamczer D, Ferrer E, Gatell JM, Niubo J, Dalmau D, Leon A, et al. Early virological failure with a combination of tenofovir, didanosine and efavirenz. Antivir Ther 2005; 10:171-177.
28. Leon A, Martinez E, Mallolas J, Laguno M, Blanco JL, Pumarola T, et al. Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine. AIDS 2005; 19:213-215.